Literature DB >> 34143297

Outcomes of paediatric kidney transplant recipients using the updated 2013/2017 Banff histopathological classification for antibody-mediated rejection.

Evgenia Preka1,2, Thivya Sekar3, Sergio C Lopez Garcia4, Olivia Shaw5, Nicos Kessaris6, Nizam Mamode6, Jelena Stojanovic4, Neil J Sebire3,7, Jon Jin Kim8, Stephen D Marks4,7.   

Abstract

BACKGROUND: After the major changes with regard to acute and chronic ABMR in the Banff classification initiated in 2013, there has been an improvement in diagnosing antibody-mediated rejection (ABMR) in adult studies but no data have been published in the paediatric population.
METHODS: We assessed 56 paediatric kidney transplant biopsies due to kidney dysfunction in patients with donor-specific antibodies (DSA) in a retrospective single-centre study between January 2006 and March 2012. The results were compared with 2003/2007 Banff classification noting the subsequent 2017 and 2019 modifications do not change the 2013 Banff classification with regard to acute antibody-mediated rejection (apart from the addition of gene transcripts/classifiers that do not affect our analysis).
RESULTS: Following the 2013 Banff classification, there were seven cases (12.5%) diagnosed with ABMR that would have been misclassified when applying the 2003/2007 classification. Evaluating the histological features of all ABMR-related cases, we report the importance of v- (intimal arteritis) and t- (tubulitis) lesions: absence of v- and t- lesions in the biopsy is related to significantly higher kidney allograft survival (OR 7.3, 95%CI 1.1-48.8, p = 0.03 and OR 5.3, 95%CI 1.2-25.5, p = 0.04 respectively). Moreover, absence of t- lesions was associated with significantly fewer rejection episodes the year after the initial biopsy (OR 5.1, 95%CI 1.4-19.8, p = 0.01).
CONCLUSIONS: Our study supports that the updated 2013 Banff classification shows superior clinicopathological correlation in identifying ABMR in paediatric kidney transplant recipients. Our results can be extrapolated to the recently updated 2019 Banff classification.

Entities:  

Keywords:  Antibody-mediated rejection; Banff classification in children; Children; Intimal arteritis; Tubulitis

Mesh:

Substances:

Year:  2021        PMID: 34143297     DOI: 10.1007/s00467-021-05103-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

1.  Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis.

Authors:  S Uehara; C M Chase; L D Cornell; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2007-01       Impact factor: 8.086

Review 2.  Antibody-mediated renal allograft rejection: diagnosis and pathogenesis.

Authors:  Robert B Colvin
Journal:  J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 10.121

3.  Treatment strategies to treat antibody-mediated rejection and to reduce donor-specific antibodies.

Authors:  Stephen D Marks
Journal:  Pediatr Transplant       Date:  2014-08

4.  A Probabilistic Approach to Histologic Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Biopsies.

Authors:  P F Halloran; K S Famulski; J Chang
Journal:  Am J Transplant       Date:  2016-08-03       Impact factor: 8.086

5.  Antibody-mediated rejection: New approaches in prevention and management.

Authors:  R A Montgomery; A Loupy; D L Segev
Journal:  Am J Transplant       Date:  2018-01       Impact factor: 8.086

Review 6.  Mechanisms of antibody-mediated acute and chronic rejection of kidney allografts.

Authors:  William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  Curr Opin Organ Transplant       Date:  2016-02       Impact factor: 2.640

7.  Impact of the Banff 2013 classification on the diagnosis of suspicious versus conclusive late antibody-mediated rejection in allografts without acute dysfunction.

Authors:  Javier Gimeno; Dolores Redondo; María José Pérez-Sáez; Dolores Naranjo-Hans; Julio Pascual; Marta Crespo
Journal:  Nephrol Dial Transplant       Date:  2016-06-16       Impact factor: 5.992

Review 8.  Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

Authors:  A Djamali; D B Kaufman; T M Ellis; W Zhong; A Matas; M Samaniego
Journal:  Am J Transplant       Date:  2014-01-08       Impact factor: 8.086

  8 in total
  1 in total

1.  Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation.

Authors:  Candice Roufosse; Jan Ulrich Becker; Marion Rabant; Daniel Seron; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.